The Diagnostic Medicine Consortium (DMC) is a global-centric movement for defining the future state of pathology and laboratory-based diagnostics. As of today, the DMC is comprised of two leading nonprofit organizations: the Association for Pathology Informatics (API) and the Project Santa Fe Foundation (PSFF), with the goal of adding other like-minded collaborating medical diagnostic societies. 

The consortium is committed to maximizing and standardizing the predictive value of actionable information generated by the diagnostic sector, so as to promote the proactive delivery of health care for individuals and populations. The goal is to shift from traditional reactive confirmation of disease conditions to proactive identification of risk for disease onset, while promoting a comprehensive approach to longitudinal chronic disease management. The DMC will also address maximizing the use of diagnostic information during episodes of acute illnesses.

At the core of the DMC’s mission is the development of a standardized approach to creating deidentified, harmonized data repositories that can serve as a comprehensive “data vault.” This critical resource will enable optimization of reference standards for population cohorts and facilitate training of artificial intelligence diagnostic algorithms. By validating the algorithms, the DMC will establish itself as a pivotal entity for submitting 510(k) applications to the FDA, creating essential pathways for product development of risk-based health care strategies that benefit patients at the individual level.

The DMC has established a set of critical objectives to realize this transformative vision:

  1. Unifying advocacy for the essential role of pathology and laboratory medicine in the era of diagnostic data intelligence.
  2. Developing impactful programming that promotes proactive prediction of disease onset and evolution.
  3. Strengthening collaborations among member organizations to achieve a global reach.
  4. Engaging key stakeholders, including public health authorities, healthcare stakeholders, and industry partners to align strategies for advancing diagnostic medicine.
  5. Securing sustainable business models to support the consortium’s mission.

 Key deliverables include:

  • Data Resources: A de-identified, harmonized repository for optimizing reference standards and training AI algorithms, qualifying for FDA 510(k) submissions as part of the product development pipeline.
  • Data Intelligence Network: A seamless platform for data sharing and querying to enhance diagnostic capabilities for individual patients across their healthcare continuum.
  • Educational Programs: Developing training and outreach initiatives to disseminate knowledge about predictive analytics and best practices, along with academic education for future pathology and clinical laboratory science in the concept of diagnostic health.

The Diagnostic Medicine Consortium embodies a steadfast commitment to innovation, prioritizing prevention, and early intervention. By leveraging the power of longitudinal data, the DMC is poised to pave the way for a more integrated and effective healthcare system that enhances patient health outcomes.